Dataset Information


5'-O-masked 2'-deoxyadenosine analogues as lead compounds for hepatitis C virus (HCV) therapeutic agents.

ABSTRACT: On the basis of our previous study on antiviral agents against the severe acute respiratory syndrome (SARS) coronavirus, a series of nucleoside analogues whose 5'-hydroxyl groups are masked by various protective groups such as carboxylate, sulfonate, and ether were synthesized and evaluated to develop novel anti-hepatitis C virus (HCV) agents. Among these, several 5'-O-masked analogues of 6-chloropurine-2'-deoxyriboside (e.g., 5'-O-benzoyl, 5'-O-p-methoxybenzoyl, and 5'-O-benzyl analogues) were found to exhibit effective anti-HCV activity. In particular, the 5'-O-benzoyl analogue exhibited the highest potency with an EC(50) of 6.1 microM in a cell-based HCV replicon assay. Since the 5'-O-unmasked analogue (i.e., 6-chloropurine-2'-deoxyriboside) was not sufficiently potent (EC(50)=47.2 microM), masking of the 5'-hydroxyl group seems to be an effective method for the development of anti-HCV agents. Presently, we hypothesize two roles for the 5'-O-masked analogues: One is the role as an anti-HCV agent by itself, and the other is as a prodrug of its 5'-O-demasked (deprotected) derivative.


PROVIDER: S-EPMC7125560 | BioStudies | 2007-01-01

REPOSITORIES: biostudies

Similar Datasets

2012-01-01 | S-EPMC7125738 | BioStudies
1992-01-01 | S-EPMC1133133 | BioStudies
2009-01-01 | S-EPMC2765047 | BioStudies
2007-01-01 | S-EPMC2064036 | BioStudies
2006-01-01 | S-EPMC2562564 | BioStudies
2009-01-01 | S-EPMC2725430 | BioStudies
2006-01-01 | S-EPMC2547132 | BioStudies
2005-01-01 | S-EPMC7092914 | BioStudies
2013-01-01 | S-EPMC3859510 | BioStudies
2012-01-01 | S-EPMC3499576 | BioStudies